Distant disease-free survival (DDFS) according to response category in neoadjuvant endocrine therapy (NET): 6-year analysis in phase III NEOS trial

H. Iwata, N. Masuda, Y. Yamamoto, T. Fujisawa, T. Toyama, N. Taira, M. Kashiwaba, S. Ohtani, T. Sakai, Y. Hasegawa, R. Nakamura, H. Akabane, Y. Shibahara, H. Sasano, T. Yamaguchi, Y. Ohashi

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)viii58
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume29
DOIs
Publication statusPublished - Oct 1 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Iwata, H., Masuda, N., Yamamoto, Y., Fujisawa, T., Toyama, T., Taira, N., Kashiwaba, M., Ohtani, S., Sakai, T., Hasegawa, Y., Nakamura, R., Akabane, H., Shibahara, Y., Sasano, H., Yamaguchi, T., & Ohashi, Y. (2018). Distant disease-free survival (DDFS) according to response category in neoadjuvant endocrine therapy (NET): 6-year analysis in phase III NEOS trial. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii58. https://doi.org/10.1093/annonc/mdy270.182